Semler Scientific (NASDAQ:SMLR) Price Target Raised to $71.00

Semler Scientific (NASDAQ:SMLR) had its price objective boosted by Lake Street Capital from $40.00 to $71.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price target suggests a potential upside of 27.41% from the stock’s previous close.

Semler Scientific Stock Performance

Shares of SMLR traded down $5.43 during mid-day trading on Friday, reaching $55.73. The company had a trading volume of 1,106,436 shares, compared to its average volume of 433,983. The company’s 50 day simple moving average is $59.91 and its 200 day simple moving average is $39.99. Semler Scientific has a 1-year low of $20.88 and a 1-year high of $81.56. The company has a market capitalization of $516.57 million, a price-to-earnings ratio of 27.29 and a beta of 1.18.

Semler Scientific (NASDAQ:SMLR) last released its earnings results on Monday, November 4th. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.35. Semler Scientific had a net margin of 27.00% and a return on equity of 20.31%. The company had revenue of $13.51 million for the quarter.

Institutional Trading of Semler Scientific

Institutional investors and hedge funds have recently made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of Semler Scientific in the second quarter valued at about $34,000. Quest Partners LLC grew its position in Semler Scientific by 48.0% during the third quarter. Quest Partners LLC now owns 2,520 shares of the company’s stock valued at $59,000 after buying an additional 817 shares during the period. US Bancorp DE grew its position in Semler Scientific by 60.8% during the third quarter. US Bancorp DE now owns 3,064 shares of the company’s stock valued at $72,000 after buying an additional 1,158 shares during the period. Sanctuary Advisors LLC bought a new position in Semler Scientific during the third quarter valued at about $104,000. Finally, Rhumbline Advisers grew its position in Semler Scientific by 27.1% during the second quarter. Rhumbline Advisers now owns 6,197 shares of the company’s stock valued at $213,000 after buying an additional 1,320 shares during the period. Hedge funds and other institutional investors own 49.37% of the company’s stock.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.